Skip to main content
Premium Trial:

Request an Annual Quote

EMBL Licenses Tripos Software

NEW YORK (GenomeWeb News) — The European Molecular Biology Laboratory has signed a license for two of Tripos' software platforms for use in its chemical biology research, the company said today.

The agreement covers Tripos' ligand-receptor docking and virtual screening software, the Surflex-Dock, and its Themis software for use in drug discovery research.

EMBL will use the software in research at the Chemical Biological Core Facility, which is a collaboration between EMBL and the German Cancer Research Center in Heidelberg and the University of Heidelberg.

EMBL has already used the Surflex-Dock software on EMBL's Linux grid of 1,400 CPUs, and five million structures from EMBL's compound database were docked into a binding site of a receptor structure. This work was completed in "about two days and yielded a promising pool of candidates for experimental testing," the company said.

Joe Lewis, who is head of the Chemical Biology Core Facility, said in a statement that the Themis software already has "provided interesting new chemical ideas contributing to new drug discovery projects."

Financial terms of the agreement were not released.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.